Immunotherapy Drug Spares Bladder Cancer Patients Surgery
Durvalumab, an immunotherapy drug, shows promise in destroying bladder cancer and preventing its return, potentially eliminating the need for radical surgery. A trial led by the Institute of Cancer Research found 85% of patients had no recurrence after on


